Arianna Scoglio

发表

p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells

A. Mauro, C. Ciccarelli, P. De Cesaris, 2005, Molecular Cancer.

The preventive phase I trial with the HIV-1 Tat-based vaccine.

G. D'offizi, P. Narciso, A. Lazzarin, 2009, Vaccine.

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

G. D'offizi, P. Narciso, A. Lazzarin, 2009, Reviews on recent clinical trials.

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

G. D'offizi, P. Narciso, A. Lazzarin, 2009, Vaccine.

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

J. Heeney, M. Ciccozzi, A. Scoglio, 2004, Vaccine.

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.

M. Colvin, M. Ciccozzi, A. Scoglio, 2003, The Journal of infectious diseases.

Efficient mucosal delivery of the HIV‐1 Tat protein using the synthetic lipopeptide MALP‐2 as adjuvant

A. Scoglio, F. Nappi, B. Ensoli, 2003, European journal of immunology.

HIV-1 Tat-based vaccines: from basic science to clinical trials.

M. Magnani, A. Scoglio, S. Moretti, 2002, DNA and cell biology.

Long-term protection against SHIV 89 . 6 P replication in 3 HIV-1 Tat vaccinated cynomolgus monkeys 4

J. Heeney, M. Ciccozzi, A. Scoglio, 2004 .

HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection

M. Magnani, A. Scoglio, S. Moretti, 2009 .

HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection1

M. Magnani, A. Scoglio, S. Moretti, 2009, The Journal of Immunology.

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.

M. Ciccozzi, A. Scoglio, A. Caputo, 2005, The Journal of infectious diseases.

Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL.

M. Magnani, A. Scoglio, S. Dominici, 2003, Vaccine.

Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART

A. Lazzarin, O. Picconi, C. Mussini, 2010, PloS one.